These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

623 related articles for article (PubMed ID: 1673721)

  • 41. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients.
    De La Mata J; Blanco FJ; Gómez-Reino JJ
    Ann Rheum Dis; 1995 Nov; 54(11):881-5. PubMed ID: 7492236
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical pharmacology of combination DMARD therapy in rheumatoid arthritis.
    Furst DE
    J Rheumatol Suppl; 1996 Mar; 44():86-90. PubMed ID: 8833062
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Long term treatment of rheumatoid arthritis. Experiences with D-penicillamine in comparison with gold and immunosuppressive drugs (author's transl)].
    Warnatz H; Scheiffarth F; Gutmann W
    Med Klin; 1975 Sep; 70(38):1509-15. PubMed ID: 810648
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
    Verstappen SM; van Albada-Kuipers GA; Bijlsma JW; Blaauw AA; Schenk Y; Haanen HC; Jacobs JW;
    Ann Rheum Dis; 2005 Jan; 64(1):38-43. PubMed ID: 15130899
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN; van den Bemt PM; Jansen TL; Houtman NM; van de Laar MA; Brouwers JR
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Gold compounds and D-penicillamine for therapy of rheumatoid arthritis].
    Miyamoto S; Inoue T
    Nihon Rinsho; 1992 Mar; 50(3):515-20. PubMed ID: 1588740
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?
    Lacaille D; Stein HB; Raboud J; Klinkhoff AV
    J Rheumatol; 2000 Aug; 27(8):1922-7. PubMed ID: 10955334
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
    O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
    J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
    Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
    Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine.
    Conaghan PG; Brooks P
    Curr Opin Rheumatol; 1995 May; 7(3):167-73. PubMed ID: 7612407
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Low-dose weekly oral methotrexate therapy for inflammatory arthritis.
    Boh LE; Schuna AA; Pitterle ME; Adams EM; Sundstrom WR
    Clin Pharm; 1986 Jun; 5(6):503-8. PubMed ID: 3720217
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Down regulation of multidrug resistance protein-1 expression in patients with early rheumatoid arthritis exposed to methotrexate as a first disease-modifying antirheumatic drug.
    Hider SL; Owen A; Hartkoorn R; Khoo S; Back D; Silman AJ; Bruce IN
    Ann Rheum Dis; 2006 Oct; 65(10):1390-3. PubMed ID: 16504991
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
    Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
    Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mechanisms of action of disease modifying antirheumatic drugs.
    Harth M
    J Rheumatol Suppl; 1992 Jan; 32():100-3. PubMed ID: 1613728
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies).
    Bensen W; Tugwell P; Roberts RM; Ludwin D; Ross H; Grace E; Gent M
    J Rheumatol; 1994 Nov; 21(11):2034-8. PubMed ID: 7869306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Toxicity of anti-rheumatic drugs in a randomized clinical trial of early rheumatoid arthritis.
    van Jaarsveld CH; Jahangier ZN; Jacobs JW; Blaauw AA; van Albada-Kuipers GA; ter Borg EJ; Brus HL; Schenk Y; van Der Veen MJ; Bijlsma JW
    Rheumatology (Oxford); 2000 Dec; 39(12):1374-82. PubMed ID: 11136881
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The total costs of drug therapy for rheumatoid arthritis. A model based on costs of drug, monitoring, and toxicity.
    Prashker MJ; Meenan RF
    Arthritis Rheum; 1995 Mar; 38(3):318-25. PubMed ID: 7880185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan.
    Ali AA; Iqbal MP; Hussain MA; Mehboobali N; Beg JA; Rahbar MH
    J Pak Med Assoc; 1998 Jan; 48(1):3-6. PubMed ID: 9610077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Differential indications in rheumatism therapy on the basis of well-known drug side effects].
    Mathies H
    Acta Med Austriaca; 1975; 2(4):156-60. PubMed ID: 1224932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.